GEHC

Business profile & competitive position

GE HealthCare Technologies Inc. operates in the Healthcare sector under the Medical - Devices industry. It generates revenue from medical devices, consumable products, services, and AI-enabled cloud and software solutions. Its customers include hospitals, health systems, and researchers across more than 160 countries. The company reports through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).

The current financial profile provides a concrete lens on its competitive position. A net margin of 7.9% and a return on equity (ROE) of 15.2% show a business that earns a meaningful but not outsized profit per dollar of sales while still delivering a double-digit return on shareholders' equity. The 15.2% ROE sits above common cost-of-equity thresholds, implying the company converts equity into earnings at a value-creating rate. The 7.9% net margin is consistent with the capital-intensive nature of imaging equipment and pharmaceutical diagnostics manufacturing, where R&D, regulatory compliance, and field service infrastructure represent substantial costs. A beta of 0.85 indicates the stock has historically moved less than the broader market, a volatility profile aligned with large, diversified healthcare-equipment franchises that carry recurring service and consumable revenue.

Financial posture

As of the current snapshot, GE HealthCare carries a market capitalization of $31.4 billion and trades at a price-to-earnings (P/E) ratio of 20.0, with the stock at $69.43. That P/E places the company at a moderate multiple relative to its 15.2% ROE and 7.9% net margin. The combination of a 20.0 P/E and a 15.2% ROE means investors are paying a mid-range premium for earnings power that converts equity into profit at a mid-teens rate.

Beyond valuation ratios, the current technical snapshot shows an RSI of 60.3 and a 50-day exponential moving average of $67.15, with the stock trading roughly 3.4% above that moving average. The beta of 0.85 reinforces a lower-beta profile relative to the broader market. No debt or cash figures are included in the current dataset, so leverage conclusions are not drawn here. The available headline metrics frame GE HealthCare as a large-cap medical-device name with a mid-teens valuation multiple and above-average returns on equity.

Strategic priorities & outlook

The company's most recent 10-K filing outlines four operational priorities. First, it intends to acquire technologies and businesses that expand, accelerate, or complement the existing business. Second, R&D is focused on creating new products, services, and solutions, discovering novel clinical applications for on-market products, and enhancing existing offerings. Third, GE HealthCare plans to continue increasing its focus on and investment in cloud, edge computing, AI, and software offerings. Fourth, it is executing a sustainability program built on five pillars, including enabling access to quality healthcare and advancing sustainable practices across the product lifecycle.

Scale supports those priorities. GE HealthCare has approximately 54,000 colleagues worldwide, including roughly 11,100 engineers and scientists. About 32% of the workforce is located in the United States. Commercial reach spans 160+ countries through roughly 9,700 sales professionals, 8,900 field service engineers, and a network of over 5,000 indirect third-party partners. The manufacturing footprint is also global, with production and assembly across 44 facilities in 17 countries. That footprint is relevant to any assessment of capacity, supply-chain complexity, and revenue diversification.

Macro & geopolitical exposure

As a Medical - Devices company with global operations, GE HealthCare sits at the intersection of healthcare policy, regulation, trade, and supply-chain risk. Medical-device companies are exposed to regulatory decisions by health authorities in major markets, reimbursement policies set by governments and private payers, and hospital capital-expenditure cycles. Because the industry relies on specialized components, semiconductors, and certain raw materials, supply-chain disruptions or input-cost inflation can pressure margins.

The company's own footprint amplifies the global nature of these exposures. With customers in more than 160 countries and production across 44 facilities in 17 countries, currency translation, cross-border tariffs, and regional trade policy are ongoing considerations rather than hypothetical risks. Healthcare budget constraints in any major geography can also affect hospital purchasing decisions for large imaging systems and associated services.

Recent developments

Recent news flow has centered on product expansion, clinical validation, regulatory milestones, and capital returns. On October 19, 2026, GE HealthCare announced it was expanding its general imaging ultrasound portfolio with LOGIQ Focus, which it described as elevating everyday ultrasound performance, according to businesswire.com. On October 17, 2026, marketbeat.com included GE HealthCare in a discussion of stocks delivering larger dividends amid market uncertainty. On October 16, 2026, research conducted at the University of Michigan and published in Anesthesia & Analgesia Practice demonstrated that GE HealthCare's End-tidal Control software may help reduce fresh gas flow, also reported by businesswire.com. On October 15, 2026, gurufocus.com reported that GE HealthCare's MINItrace Magni achieved CE Mark and that Copper-64 expands the PETtrace Solid Target Platform beyond Gallium-68.

These items collectively show near-term activity across new hardware launches, software validation, radiopharmaceutical platform expansion, and shareholder returns. The most recent ultrasound and radiopharmaceutical announcements tie back to both the Imaging and Pharmaceutical Diagnostics segments, while the End-tidal Control research aligns with the Patient Care Solutions portfolio.

Earnings behavior & post-earnings drift

GE HealthCare has beaten consensus earnings expectations in 7 of the last 8 reported quarters, an 88% beat rate, with an average earnings surprise of 7.3%. Despite that strong hit rate, the average 5-day price move after earnings across those same quarters was -1.24%, and the post-earnings drift is classified as down. That is a notable disconnect: earnings beats have not reliably produced positive follow-through in the stock price.

The last four reports illustrate the pattern. On July 29, 2026, GE HealthCare reported EPS of $1.13 against an estimate of $1.04, an 8.7% positive surprise, yet the stock fell 2.73% the next day and 2.31% over the following five days. On April 29, 2026, the company missed by 4.8% with EPS of $0.99 versus an estimate of $1.04, but the stock rose 2.27% the next day and 3.78% over the following five days. On February 4, 2026, a 2.9% beat with EPS of $1.44 versus $1.40 was followed by a 0.39% next-day decline and a 4.15% drop over the next five days. On October 29, 2025, a 1.9% beat with EPS of $1.07 versus $1.05 was met with a 3.08% next-day decline and a 2.29% five-day drop.

In other words, over the last year, a positive earnings surprise has not translated into a positive post-earnings drift for GE HealthCare, while the lone miss during that window was followed by a positive drift. The next scheduled report is October 28, 2026, before the market open, with a consensus EPS estimate of $1.21.

For a deeper dive into institutional positioning, sell-side models, and the current consensus around GE HealthCare's October 28 report, review the full institutional verdict rather than relying on summary metrics alone.